Eye drops may offer a new way to read without glasses — a trial puts them to the test

NCT ID NCT07723716

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether CTO0307, a pilocarpine eye drop, can improve near vision in adults aged 40 to 64 with presbyopia — the age-related difficulty seeing up close. Participants receive either the active drop or a placebo for four weeks. The main question is whether more people in the treatment group gain at least three lines on a near-vision chart three hours after each dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pilocarpine eye drops
What this could lead to
If effective, CTO0307 could offer a non-surgical option to temporarily improve near vision in people with presbyopia.
What could go wrong
This is an early-phase trial with a small number of participants. The effect may be modest or temporary, and eye drops can cause side effects like blurred vision or eye irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRESBYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kangbook Samsung Medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.